Alnylam Pharmaceuticals, Inc. (LON:0HD2)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 15.04B -66.2% |
| Revenue (ttm) | 3.78B +56.2% |
| Net Income | 2.00B +2,136.9% |
| EPS | 14.37 +2,056.9% |
| Shares Out | n/a |
| PE Ratio | 7.86 |
| Forward PE | 14.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,615 |
| Open | 157.58 |
| Previous Close | 156.89 |
| Day's Range | 149.30 - 158.82 |
| 52-Week Range | 150.05 - 477.82 |
| Beta | 0.44 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
News
City Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of City Therapeutics (CTY) with an Outperform rating and $46 price target. The company, which is developing siRNA medicines, was co-founded by Alnylam’s (ALNY) founding ...
Alnylam says Regeneron advances CIDEBsiRNA with FIH results in MASLD patients
Alnylam Pharmaceuticals (ALNY) announced that its collaborator, Regeneron Pharmaceuticals (REGN), shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CID...
Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared in...
Alnylam announces 5-year HELIOS-B data showing benefit of Amvuttra in ATTR-CM
Alnylam (ALNY) Pharmaceuticals announced new data at the American Heart Association Scientific Sessions 2026. The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension perio...
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sess...
Alnylam price target lowered to $250 from $320 at Citi
Citi lowered the firm’s price target on Alnylam (ALNY) to $250 from $320 and keeps a Buy rating on the shares. The firm cites reset of Amvuttra’s net price for…
Alnylam announces $1B share repurchase program
Alnylam’s (ALNY) Board of Directors has authorized the repurchase of up to $1 billion of the Company’s common stock, reflecting its confidence in the Company’s long-term growth prospects and its…
Alnylam CCO Tanguler to step down
Alnylam (ALNY) announced that Tolga Tanguler will depart his role as Chief Commercialization Officer. The Company is working with an executive search firm to support the selection of its next…
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share re...
Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies...
Alnylam to present five-year HELIOS-B data at AHA, ISA 2026
Alnylam (ALNY) Pharmaceuticals will present new clinical and real-world data at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois, and the Interna...
Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the Ame...
Alnylam price target lowered to $323 from $429 at Canaccord
Canaccord analyst Whitney Ijem lowered the firm’s price target on Alnylam (ALNY) to $323 from $429 and keeps a Buy rating on the shares. The firm updated its odel following…
Truist downgrades Alnylam on less certain Amvuttra outlook
Truist analyst Danielle Brill downgraded Alnylam (ALNY) to Hold from Buy with a price target of $225, down from $315. Following the Q3 report, the outlook for Amvuttra “has become…
Alnylam price target lowered to $380 from $450 at Barclays
Barclays lowered the firm’s price target on Alnylam (ALNY) to $380 from $450 and keeps an Overweight rating on the shares post the Q3 report. The firm says Amvuttra commercial…
Alnylam downgraded to Hold from Buy at Truist
Truist downgraded Alnylam (ALNY) to Hold from Buy with a $225 price target
Alnylam price target lowered to $350 from $410 at Freedom Broker
Freedom Broker lowered the firm’s price target on Alnylam (ALNY) to $350 from $410 and keeps a Buy rating on the shares. The main change from the firm’s previous estimates…
Alnylam price target lowered to $240 from $300 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $240 from $300 and keeps an Equal Weight rating on the shares. In-line TTR sales were supported by one-time…
Alnylam price target lowered to $354 from $482 at TD Cowen
TD Cowen lowered the firm’s price target on Alnylam (ALNY) to $354 from $482 and keeps a Buy rating on the shares. The fim updated its model following inline Q3…
Alnylam price target lowered to $320 from $536 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Alnylam (ALNY) to $320 from $536 and keeps a Buy rating on the shares. Alnylam delivered an in-line Q3 but guided to…
Bernstein downgrades Alnylam to Market Perform, lowers target to $199
Bernstein downgraded Alnylam (ALNY) to Market Perform from Outperform with a price target of $199, down from $376, after the company stated their intention to refine TRITON-CM design to account…
Alnylam downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst William Pickering downgraded Alnylam (ALNY) to Market Perform from Outperform.
Alnylam price target lowered to $329 from $354 at UBS
UBS analyst Joon Lee lowered the firm’s price target on Alnylam (ALNY) to $329 from $354 and keeps a Buy rating on the shares. Alnylam’s outlook moderates near term, but…
Alnylam Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 net product revenue rose 52% YoY to $1.29B, led by TTR, but AMVUTTRA demand growth lagged expectations. 2026 TTR sales are expected at the low end of guidance amid access and ordering uncertainty; TRITON-CM enrollment expanded and brezosiran advanced toward pivotal testing.
Alnylam Pharmaceuticals Earnings release: Q3 2026
Alnylam Pharmaceuticals released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.